Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy for Stage I Lung Adenocarcinoma with Micropapillary Component
NCT03351842Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Cisplatin micelle injection (HA132), carboplatin and pemetrexed in lung adenocarcinoma (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Disease-Free Survival Rate at 60 months. Started Sep 2017; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)carboplatinpemetrexed
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03351842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351842.